A novel resveratrol analogue HS-1793 treatment overcomes the resistance conferred by Bcl-2 and is associated with the formation of mature PML nuclear bodies in renal clear cell carcinoma Caki-1 cells

  • Authors:
    • Seung Hun Jeong
    • Jee Suk Lee
    • Na Young Jeong
    • Tae Hyun Kim
    • Ki Soo Yoo
    • Suhee Song
    • Hongsuk Suh
    • Taeg Kyu Kwon
    • Bong Soo Park
    • Young Hyun Yoo
  • View Affiliations

  • Published online on: December 1, 2009     https://doi.org/10.3892/ijo_00000453
  • Pages: 1353-1360
Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )
Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )


Abstract

Bcl-2 protects cancer cells from the apoptotic effects of various chemotherapeutic agents. Inhibition or downregulation of Bcl-2 represents a new therapeutic approach to bypass chemoresistance in cancer cells. Previously we designed and synthesized the resveratrol analogue HS-1793 displaying stronger antitumor efficacy than resveratrol and further demonstrated the HS-1793 resistance conferred by Bcl-2 in human leukemic U937 cells. We undertook this study to determine if HS-1793 treatment can bypass the anti-apoptotic effects of Bcl-2 in human renal cancer cells, with a specific focus on the involvement of promyelocytic leukemia nuclear bodies (PML-NBs). Experiments were conducted with Bcl-2-overexpressing human renal clear cell carcinoma Caki-1 cells. Various apoptosis assessment assays demonstrated that HS-1793 overcomes the resistance conferred by Bcl-2 in Caki-1 cells by inducing apoptosis. We elucidated that HS-1793-induced formation of mature promyelocytic leukemia (PML) nuclear bodies (NBs) correlates with overcoming the anti-apoptotic effects of Bcl-2 in Caki-1 cells. Our findings show that the resveratrol analogue HS-1793 might provide a novel promising strategy for overcoming the resistance conferred by Bcl-2 via PML protein and the formation of mature PML-NBs.

Related Articles

Journal Cover

December 2009
Volume 35 Issue 6

Print ISSN: 1019-6439
Online ISSN:1791-2423

Sign up for eToc alerts

Recommend to Library

Copy and paste a formatted citation
x
Spandidos Publications style
Jeong SH, Lee JS, Jeong NY, Kim TH, Yoo KS, Song S, Suh H, Kwon TK, Park BS, Yoo YH, Yoo YH, et al: A novel resveratrol analogue HS-1793 treatment overcomes the resistance conferred by Bcl-2 and is associated with the formation of mature PML nuclear bodies in renal clear cell carcinoma Caki-1 cells. Int J Oncol 35: 1353-1360, 2009
APA
Jeong, S.H., Lee, J.S., Jeong, N.Y., Kim, T.H., Yoo, K.S., Song, S. ... Yoo, Y.H. (2009). A novel resveratrol analogue HS-1793 treatment overcomes the resistance conferred by Bcl-2 and is associated with the formation of mature PML nuclear bodies in renal clear cell carcinoma Caki-1 cells. International Journal of Oncology, 35, 1353-1360. https://doi.org/10.3892/ijo_00000453
MLA
Jeong, S. H., Lee, J. S., Jeong, N. Y., Kim, T. H., Yoo, K. S., Song, S., Suh, H., Kwon, T. K., Park, B. S., Yoo, Y. H."A novel resveratrol analogue HS-1793 treatment overcomes the resistance conferred by Bcl-2 and is associated with the formation of mature PML nuclear bodies in renal clear cell carcinoma Caki-1 cells". International Journal of Oncology 35.6 (2009): 1353-1360.
Chicago
Jeong, S. H., Lee, J. S., Jeong, N. Y., Kim, T. H., Yoo, K. S., Song, S., Suh, H., Kwon, T. K., Park, B. S., Yoo, Y. H."A novel resveratrol analogue HS-1793 treatment overcomes the resistance conferred by Bcl-2 and is associated with the formation of mature PML nuclear bodies in renal clear cell carcinoma Caki-1 cells". International Journal of Oncology 35, no. 6 (2009): 1353-1360. https://doi.org/10.3892/ijo_00000453